Form 4: Stoke Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Jonathan Allan, GENERAL COUNSEL & CORP SEC of Stoke Therapeutics, Inc., sold 627 shares of common stock on October 2, 2026 for $26.33 per share.
Summary
- Open-market sale: disposed of 627 Common Stock at $26.33 ($16,509) on October 2, 2026; holds 20,598 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $16,509 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jonathan Allan — Officer (GENERAL COUNSEL & CORP SEC)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-02 | Open-market sale | Common Stock | 627 | $26 | $16.5K | 20,598 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-02 | Open-market sale (627 shares) |
Keywords
insider transaction, Form 4, STOK, Stoke Therapeutics, Inc., bearish, Jonathan Allan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.